Instead of struggling with weekly injections, patients may soon be able to swallow a daily pill to lose weight. Both the ...
An Alzheimer drug had never represented more than 5% of Novo’s share price, the Kepler analysts said. As a result, any cuts ...
Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...
17h
Semaglutide fails to slow progression of Alzheimer’s in highly anticipated trials, Novo Nordisk says
An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...
Loosely regulated online platforms are promoting powerful obesity shots as a universal weight-loss solution. Photographer: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback